Cabozantinib, CABODX, Cabozantinib 60mg

Manufacturer: Laos Daxiong Pharmaceutical

Introduction: Cabozantinib was approved by the FDA on November 29, 2012 for the treatment of progressive and metastatic medullary thyroid cancer; for the treatment of advanced renal cancer; and for the second-line treatment of advanced thyroid cancer. Cabozantinib is a multi-receptor tyrosine kinase inhibitor. Cabozantinib inhibits the activity of RET, hepatocyte growth receptor receptor, vascular endothelial growth receptor receptor 1 (VEGFR-1, VEGFR-2, VEGFR-3), stem cell growth receptor (KIT), tyrosine kinase inhibitor (TRKB), FMS-like tyrosine inhibitor 3 (FLT-3), AXL and epithelial growth factor-like domain tyrosine inhibitor 2 (TIE-2). The above tyrosine inhibitors. .